title: Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.
abstract: We report the case of a 55-year-old man with stage IV lung adenocarcinoma who received carboplatin-paclitaxel-bevacizumab chemotherapy as second-line therapy. After four cycles of chemotherapy, he experienced syncope with a decrease in blood pressure. Electrocardiography (ECG) revealed atrial fibrillation. Cardiac ultrasonography showed a markedly reduced ejection fraction (45%), with moderate decrease in comparison to that before chemotherapy (66%). Bisoprolol fumarate was initiated, and the conversion to sinus rhythm was detected by ECG 4 days after the syncope. At that time, no improvement in the ejection fraction was detected. Bevacizumab-associated cardiotoxicity was suspected, and bevacizumab maintenance therapy was discontinued, although the chemotherapy achieved a stable disease status based on the Response Evaluation Criteria in Solid Tumors. Two months after bevacizumab cessation, the ejection fraction improved to pretreatment level (62%). To the best of our knowledge, this is the first report on cardiogenic syncope due to left ventricular dysfunction that is most consistent with bevacizumab-associated cardiotoxicity in non-small cell lung cancer (NSCLC). Our results indicate that bevacizumab could lead to cardiotoxicity in patients with NSCLC and suggest the importance of the follow-up cardiac ultrasonography.
authors.affiliation: Department of Respiratory Medicine, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Haruka
authors.initials: H
authors.lastname: Chino
authors.affiliation: Department of Respiratory Medicine, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Amano
authors.affiliation: Department of Respiratory Medicine, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yamauchi
authors.affiliation: Department of Cardiovascular Medicine, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Jun
authors.initials: J
authors.lastname: Matsuda
authors.affiliation: Department of Cardiovascular Medicine, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Norihiko
authors.initials: N
authors.lastname: Takeda
authors.affiliation: Department of Respiratory Medicine, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Goh
authors.initials: G
authors.lastname: Tanaka
authors.affiliation: Department of Clinical Laboratory, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Daiya
authors.initials: D
authors.lastname: Takai
authors.affiliation: Department of Respiratory Medicine, the University of Tokyo Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: Takahide
authors.initials: T
authors.lastname: Nagase
keywords: Non-small cell lung cancer (NSCLC); bevacizumab; cardiotoxicity; chemotherapy; vascular endothelial growth factor (VEGF)